Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04922307
NA

Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer

Sponsor: Vanderbilt University Medical Center

View on ClinicalTrials.gov

Summary

The Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer Trial (RESTRICT). The primary objective is to reduce the number of units of allogenic blood transfusion in locally advanced kidney cancer (≥ cT2). Secondary objectives include reduction in perioperative complications, assessment of recurrence free-survival and improving overall survival.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

240

Start Date

2021-07-23

Completion Date

2027-06-15

Last Updated

2025-11-12

Healthy Volunteers

No

Conditions

Interventions

PROCEDURE

Blood Sparing Protocol

Acute Normovolemic Hemodilution, Cell Saver, and/or Veno-venous Bypass

PROCEDURE

Standard Blood Replacement

Allogenic blood transfusion as determined intra-operatively

Locations (3)

H. Lee Moffitt Cancer Center

Tampa, Florida, United States

Winship Cancer Institute at Emory University

Atlanta, Georgia, United States

Vanderbilt University Medical Center

Nashville, Tennessee, United States